Douglas W Losordo MD

Cardiology•New York, NY

Executive Vice President, Global Head of R&D, Chief Medical Officer.

Join to View Full Profile

420 Lexington AveNew York, NY 10011

Education & Training

St Elizabeth's Medical CenterResidency, Internal Medicine, 1983 - 1986
University of Vermont College of MedicineClass of 1983
St Elizabeth's Medical CenterFellowship, Cardiovascular Disease

Certifications & Licensure

NY State Medical License 2014 - 2025
IL State Medical License 2007 - 2020
MA State Medical License 1984 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FACC) American College of Cardiology

Clinical Trials

VEGF Gene Transfer for Diabetic Neuropathy Start of enrollment: 2002 Dec 01
Completed
Phase 1, Phase 2
Stem Cell Mobilization and VEGF Gene Transfer for Heart Failure Start of enrollment: 2008 Jul 01
Withdrawn
Phase 1
VEGF Gene Transfer for Critical Limb Ischemia
Completed
Phase 1
Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain) Start of enrollment: 2006 Apr 01
Unknown status
Phase 1
Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia Start of enrollment: 2007 Dec 01
Completed
Phase 1, Phase 2
Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure Start of enrollment: 2010 Feb 01
Completed
Phase 1
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study) Start of enrollment: 2016 Feb 01
Completed
Phase 2
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease Start of enrollment: 2018 Apr 19
Completed
Phase 2
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage Start of enrollment: 2020 Oct 05
WITHDRAWN
PHASE1
Join now to see all

Publications & Presentations

PubMed

22 citations
Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction.
Timothy D Henry, C Noel Bairey Merz, Janet Wei, Michel T Corban, Odayme Quesada
Circulation. Cardiovascular Interventions. 2022-02-01
16 citations
CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina.
Grace L. Johnson, Timothy D. Henry, Thomas J. Povsic, Douglas W. Losordo, Ross Garberich
Stem Cells Translational Medicine. 2020-06-12
15 citations
Autologous CD34+ Cell Therapy for Ischemic Tissue Repair.
William K. Sietsema, Atsuhiko Kawamoto, Hiroshi Takagi, Douglas W. Losordo
Circulation Journal. 2019-06-25

Press Mentions

Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerNovember 17th, 2020
AHA: Caladrius Single Injection Helps Heart Disease That Hits Women the HardestNovember 18th, 2019
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019November 16th, 2019
Join now to see all

Grant Support

Small Animal Surgery And HistologyNational Heart, Lung, And Blood Institute2012
Role Of PAI-1 In Cardiovascular Repair And FibrosisNational Heart, Lung, And Blood Institute2012
Peptide Amphiphiles To Augment Progentitor Cell TherapiesNational Heart, Lung, And Blood Institute2012
Mitochondrial Defects In Epcs In Diabetes And AgingNational Heart, Lung, And Blood Institute2012
FACS Analysis And Cell SortingNational Heart, Lung, And Blood Institute2012
Epigenetic Modulation Of EPC For CardiomyogenesisNational Heart, Lung, And Blood Institute2012
Advanced Molecular ImagingNational Heart, Lung, And Blood Institute2012
Administrative CoreNational Heart, Lung, And Blood Institute2012
Therapeutic Angiogenesis In Vascular Medicine IVNational Heart, Lung, And Blood Institute2011
Novel Approaches To Ischemic Tissue RepairNational Heart, Lung, And Blood Institute2011
Cardiovascular Regenerative MedicineNational Heart, Lung, And Blood Institute2011
Autologous CD34+ Cell Therapy For Therapeutic Angiogenesis In Advanced PADNational Heart, Lung, And Blood Institute2011
Therapeutic Angiogenesis In Vascular Medicine IIINational Heart, Lung, And Blood Institute2009–2010
Novel Approaches To Ischemic Tissue RepairNational Heart, Lung, And Blood Institute2009–2010
Role Of Progenitor Cells In Cardiovascular MedicineNational Heart, Lung, And Blood Institute2007–2010
Autologous CD34+ Cell Therapy For Therapeutic Angiogenesis In Advanced PADNational Heart, Lung, And Blood Institute2007–2010
Progenitor Cells In Vascular BiologyNational Heart, Lung, And Blood Institute2007–2008
Restenosis And Endothelial ProliferationNational Heart, Lung, And Blood Institute2007
Role Of Progenitor Cells In Cardiovascular MedicineNational Heart, Lung, And Blood Institute2006
Autologous CD34+ Cell Therapy For Therapeutic Angiogenesis In Advanced PADNational Heart, Lung, And Blood Institute2006
Progenitor Cells In Vascular BiologyNational Heart, Lung, And Blood Institute2005–2006
Restenosis And Endothelial ProliferationNational Heart, Lung, And Blood Institute1999–2006
VEGF Gene Transfer To Prevent Coronary Artery RestenosisNational Heart, Lung, And Blood Institute2001–2005
Core--TrainingNational Heart, Lung, And Blood Institute2001–2005
Therapeutic Angiogenesis In Vascular Medicine IINational Heart, Lung, And Blood Institute2002–2004
Center Of Excellence In Gene Therapy(Program Project)National Heart, Lung, And Blood Institute2002–2004
Re-Endothelialization And Restenosis IINational Heart, Lung, And Blood Institute2001–2004
Estrogen, Angiogenesis And Endothelial Progenitor CellsNational Heart, Lung, And Blood Institute2001–2004
Estrogen For Prevention Of Restenosis In Older WomenNational Institute On Aging1999–2000